Related Experiment Videos
Sisomicin in surgical infections. Laboratory and clinical studies
Abstract:
A clinical and bacteriological study to evaluate the effectiveness and toxicity of sisomicin in the treatment of surgical infections is described. Fifteen patients received i.m. injections of 150 or 225 mg/day for seven days. The daily doses was divided into three applications. The mean serum levels at the first hour were 5.26 +/- 2.41 microgram/ml and at the seventh hour 1.0 +/- 1.19 microgram/ml. Similar values were determined on the seventh day of treatment with sisomicin: 6.36 +/- 2.36 microgram/ml one hour, 1.17 +/- 1.67 microgram/ml seven hours after i.m. injection. All the microorganisms isolated had MICs below the sisomicin levels measured. The clinical results were assessed as "excellent" in 11 patients. Therapeutic results were considered as "fair" in three patients. The clinical conditions of one patient affected by osteomyelitis following osteosynthesis of the femur was not improved by treatment. No side effects were observed.
Insights
Sisomicin effectively treated surgical infections in 14 of 15 patients with no observed side effects. This antibiotic demonstrated favorable serum levels and potent antimicrobial activity against isolated pathogens.
Area of Science:
- Clinical microbiology
- Pharmacology
- Infectious diseases
Background:
- Surgical infections pose significant treatment challenges.
- Aminoglycoside antibiotics are crucial for combating bacterial infections.
- Sisomicin is an aminoglycoside antibiotic requiring efficacy and safety evaluation.
Purpose of the Study:
- To assess the clinical effectiveness of sisomicin in treating surgical infections.
- To evaluate the toxicity profile of sisomicin therapy.
- To determine sisomicin's pharmacokinetic properties and antimicrobial activity.
Main Methods:
- A clinical trial involving 15 patients with surgical infections.
- Intramuscular administration of sisomicin at 150 or 225 mg/day for seven days.
- Bacteriological analysis to determine minimum inhibitory concentrations (MICs) and serum drug level monitoring.
Main Results:
- Sisomicin achieved excellent clinical outcomes in 11 patients and fair results in three.
- All isolated microorganisms exhibited MICs below measured sisomicin serum levels.
- No adverse side effects were reported during the seven-day treatment period.
Conclusions:
- Sisomicin demonstrates significant efficacy and a favorable safety profile for treating surgical infections.
- Therapeutic sisomicin concentrations were achieved, exceeding MICs of causative pathogens.
- Further investigation into sisomicin's role in surgical infection management is warranted.